Previous close | 16.95 |
Open | 17.50 |
Bid | 16.15 x 200 |
Ask | 16.24 x 400 |
Day's range | 15.94 - 17.50 |
52-week range | 3.94 - 17.83 |
Volume | |
Avg. volume | 526,717 |
Market cap | 842.32M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Consistent with Analyst Projections Amidst Clinical Advancements
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.